Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $44.8 million versus the consensus estimate of $49 million.

GUIDANCE:

Puma Biotech sees Q2 2026 revenue of $52-55 million, versus the consensus of $52 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.